-transparent.png){kind=logo}
The pharmacological properties of 4'-ethyl-2-methyl-3-pyrrolidinopropiophenone hydrochloride (HSR-770), a new centrally acting muscle relaxant, were investigated in experimental animals. HSR-770, within a dose range of 1-10 mg/kg i.v., relaxed alpha- and gamma-rigidities in rats, the dose required to relax gamma-rigidity being lower than the dose required to relax alpha-rigidity. When HSR-770 was intraduodenally (i.d.) administered within a dose range of 25-50 mg/kg, the relaxant activity on alpha-rigidity was potent and long-lasting in comparison with eperisone or tolperisone. HSR-770 inhibited flexor reflex more strongly than patellar reflex in a dose-dependent manner within a dose range of 2.5-10 mg/kg i.v. or 25 and 50 mg/kg i.d. in anesthetized cats. In spinal cts, HSR-770 (5 and 10 mg/kg i.v.) inhibited flexor reflex but this potency was weaker than that in anesthetized cats. HSR-770 (12.5-50 mg/kg i.d.) inhibited he crossed extensor reflex in anesthetized rats. In spinal cats, HSR-770 inhibited mono- and polysynaptic reflex potentials to the same extent and also depressed dorsal root reflex potential at 5 and 10 mg/kg i.v. HSR-770 at a dose (50 mg/kg p.o.) which exerted muscle relaxant activity on both rigidity and flexor reflex, had little effect on spontaneous motor activity (mice), hexobarbital-induced sleeping time (mice) and conditioned avoidance response (rats). These results indicate that HSR-770 is a potent centrally acting muscle relaxant and that its central nervous system depressant activity is relatively weak.
K Morikawa, and
M Oshita, and
M Yamazaki, and
N Ohara, and
F Mizutani, and
H Kato, and
Y Ito, and
H Kontani, and
R Koshiura
September 1987,
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan,
K Morikawa, and
M Oshita, and
M Yamazaki, and
N Ohara, and
F Mizutani, and
H Kato, and
Y Ito, and
H Kontani, and
R Koshiura
May 1985,
Archives internationales de pharmacodynamie et de therapie,
K Morikawa, and
M Oshita, and
M Yamazaki, and
N Ohara, and
F Mizutani, and
H Kato, and
Y Ito, and
H Kontani, and
R Koshiura
June 1997,
Arzneimittel-Forschung,
K Morikawa, and
M Oshita, and
M Yamazaki, and
N Ohara, and
F Mizutani, and
H Kato, and
Y Ito, and
H Kontani, and
R Koshiura
January 1995,
European journal of pharmacology,
K Morikawa, and
M Oshita, and
M Yamazaki, and
N Ohara, and
F Mizutani, and
H Kato, and
Y Ito, and
H Kontani, and
R Koshiura
May 1966,
The Journal of pharmacy and pharmacology,
K Morikawa, and
M Oshita, and
M Yamazaki, and
N Ohara, and
F Mizutani, and
H Kato, and
Y Ito, and
H Kontani, and
R Koshiura
October 1997,
European journal of pharmacology,
K Morikawa, and
M Oshita, and
M Yamazaki, and
N Ohara, and
F Mizutani, and
H Kato, and
Y Ito, and
H Kontani, and
R Koshiura
September 1968,
Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
K Morikawa, and
M Oshita, and
M Yamazaki, and
N Ohara, and
F Mizutani, and
H Kato, and
Y Ito, and
H Kontani, and
R Koshiura
January 1988,
General pharmacology,
K Morikawa, and
M Oshita, and
M Yamazaki, and
N Ohara, and
F Mizutani, and
H Kato, and
Y Ito, and
H Kontani, and
R Koshiura
February 1970,
British journal of pharmacology,
K Morikawa, and
M Oshita, and
M Yamazaki, and
N Ohara, and
F Mizutani, and
H Kato, and
Y Ito, and
H Kontani, and
R Koshiura
June 1978,
Archives internationales de pharmacodynamie et de therapie,
